The EPS miss is notable but typical for a pre-revenue biotech investing heavily in clinical and commercial readiness. The stock will trade on upcoming catalysts: AUA data presentation (May 15-18), NSCLC phase 3 initiation (June 2026), and BLA submission (Q4 2026). Monitor for any safety or efficacy signals from the AUA presentation that could derail or accelerate the BLA timeline.
Price Chart
Executive Summary
Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no revenue. The company highlighted progress toward a BLA submission for aglatimagene in prostate cancer in Q4 2026, a planned pivotal phase 3 NSCLC trial initiation in June 2026, and a cash runway into Q1 2028. The EPS miss is significant for a pre-revenue biotech, but the clinical and regulatory catalysts dominate the narrative.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.54 vs consensus -$0.33 (65.6% miss)
- No revenue reported (pre-revenue clinical-stage company)
- Cash and cash equivalents of $194.8M as of March 31, 2026, sufficient into Q1 2028
- BLA submission for aglatimagene in localized prostate cancer planned for Q4 2026
- Pivotal phase 3 NSCLC trial of aglatimagene expected to initiate in June 2026
- Extended survival tail data from phase 2a NSCLC trial reported (50% of per-protocol patients surviving beyond 24 months)
- Commercial partnership with EVERSANA announced for potential U.S. launch of aglatimagene
- $100M royalty funding agreement with RTW Investments, contingent on FDA approval
- Net loss of $8.9M in Q1 2026 vs net income of $7.4M in Q1 2025, driven by change in fair value of warrant liabilities
Financial Impact
EPS miss of $0.21 vs consensus; net loss of $8.9M; cash burn rate ~$16.3M/quarter in operating expenses
Risk Factors
- BLA submission or FDA approval may be delayed or denied
- Phase 3 NSCLC trial may fail to meet endpoints
- Cash burn rate may increase, requiring additional financing before Q1 2028
- Royalty funding agreement with RTW is contingent on FDA approval
- Competition from other oncolytic virus and immunotherapy platforms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294901 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers